Related Experiment Video

Updated: May 31, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

LRRK2 Parkinson's disease: from animal models to cellular mechanisms

Chin-Hsien Lin1, Pei-I Tsai, Ruey-Meei Wu

  • 1Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.

Reviews in the Neurosciences
|June 18, 2011
PubMed

Insights

Mutations in leucine-rich repeat kinase 2 (LRRK2) are key to Parkinson's disease (PD) development. Understanding LRRK2's cellular roles and how mutations impact pathways is crucial for developing new PD treatments.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Mutations in leucine-rich repeat kinase 2 (LRRK2) are a significant genetic factor in Parkinson's disease (PD) etiology.
  • LRRK2 mutations are frequently found in the protein's catalytic domain, implicating altered enzymatic activity in PD pathogenesis.

Purpose of the Study:

  • To review recent research on how LRRK2 mutations affect cellular pathways and neuronal degeneration in Parkinson's disease.
  • To summarize current understanding of the endogenous functions of the LRRK2 protein within cellular environments.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of studies investigating LRRK2's role in cellular pathways and neurodegeneration.
  • Synthesis of evidence on LRRK2's endogenous cellular functions.

Main Results:

  • LRRK2 mutations disrupt critical cellular pathways, contributing to the neurodegenerative processes observed in Parkinson's disease.
  • Research highlights the complex endogenous functions of LRRK2, which are essential for normal cellular operations.
  • Understanding these mechanisms provides insights into PD pathophysiology.

Conclusions:

  • Altered LRRK2 enzymatic activity due to mutations is a key driver of Parkinson's disease.
  • Elucidating LRRK2's normal functions and the impact of mutations offers a foundation for novel therapeutic strategies.
  • Further research into LRRK2 is vital for advancing Parkinson's disease treatment and understanding.

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.